1、380 SD0 3/ 2007 M 10 2 5 Chin Med Biotechnol, October 2007, Vol. 2, No. 5 8 t 0Z tT0 3 Tb MM yyVra ?1“ YVM/ 9t ?9Ft4tbM Vs_Ma M DNA Fb ? F )ttt Pep3 718b tt MLt 7 3tY K ? s8z bs0 = N C tt t vv19bLt M1t F ) ?%Z VC? 20b|Lt t Lt Bt V Pt A4b %*t Arg-Gly-Asp 2 m H9 3Z TA# C4YVt Y=?diazaethyleneglycol 3 ?
2、 “88 ? 7 O9 421bArg-Gly-Asp-Val-Tyr ? h% K562 8* Siemion 22t Cys c= ;o t A9 b Z Tt Vs nM ta M t23a M t24ac= ; Bt25-26# B t27-29bM V P? 3 vMb FtM t A30b et H-Tyr-cD-Cys-Phe-Cys NH2 H-Tyr-cD-Cys-Phe-D-CysNH2sY s8 F4=J-CH2-CH2- =J-CH = CH-9= ;ot et Ah 31bTamilarasu 32YV9 E?Ct -Ml Lt 3 7 t YKl N E Bt |
3、XrTb9t+ Pt 0! s1 7? -b “ -t 0/ aZEsT9Cb et s0? 3 M8 =T HW = .4 3v z t 0Sb e9i“ e0a Xl5yNs a e ar 3 t e 1Z_bYVt ? Pls0tA44 y ls0t aS NbYVyVrtZ i l 0?1Z_ g - tVr #/B/ 7YV eyM4tZ |?vTbt I nMt YsrtZE m S s0 !9 tb ID 1 Zhu LP. Protein glycosylation and B cell immunity. Shanghai J Immunol, 2001, 21(4):193
4、-194. (in Chinese) . B % f . Z f , 2001, 21(4):193-194. 2 Rosci M, Horvat S. Transformations of bioactive peptides in the presence of sugars-Characterization and stability studies of the adducts generated via the Maillard reaction. Bioorg Med Chem, 2006, 14(14):4933-4943. 3 Goodson RJ, Katre NV. Sit
5、e-directed PEGylation of recombinant 382 SD0 3/ 2007 M 10 2 5 Chin Med Biotechnol, October 2007, Vol. 2, No. 5 interleukin-2 at its glycosylation site. Biotechnology, 1990, 8(4): 343-346. 4 Yu AP, Jiang ZH, Zhong GS, et al. Isolation of PEGylated hirudin and analysis on its activity. Pharm Biotechno
6、l, 2004, 11(5):302-305. (in Chinese) , , , . Y=? e s Bs . 0 3/ , 2004, 11(5):302-305. 5 Pan CQ, Buxton JM, Yung SL, et al. Design of a long acting peptide fFunctioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem, 2006, 281(18): 12506-12515. 6 Li
7、geti M, Bsze S, Csmpai A, et al. Synthesis of enzymatically resistant nociceptin-related peptides containing a carbamic acid residue. J Pept Sci, 2006, 12(7):481-490. 7 Zobel K, Koehler MF, Beresini MH, et al. Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bio
8、org Med Chem Lett, 2003, 13(9):1513-1515. 8 Chen Y, Vasil AI, Rehaume L, et al. Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem Biol Drug Des, 2006, 67(2):162-173. 9 Boeglin D, Xiang Z, Sorenson NB, et al. Aza-scanning of the potent melano
9、cortin receptor agonist Ac-His-d-Phe-Arg-Trp-NH. Chem Biol Drug Des, 2006, 67(4):275-283. 10 DUrsi AM, Giannecchini S, Esposito C, et al. Development of antiviral fusion inhibitors:short modified peptides derived from the transmembrane glycoprotein of feline immunodeficiency virus. Chembiochem, 2006
10、, 7(5):774-779. 11 Zheng J, Ma B, Tsai CJ, et al. Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35. Biophys J, 2006, 91(3):824-833. 12 Pless J. The history of somatostatin analogs. J Endocrinol Invest, 2005, 28(11 Suppl):1-4. 13 OFagain C. Enzyme st
11、abilization:recent experimental progress. Enzyme Microb Technol, 2003, 33(2):137-149. 14 Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther, 2002, 303(2):540-548. 15
12、Chang SH, Gong X, Yang ZY, et al. Expression in pichia pastoris and properties of human serum albumin-interferon 2b chimera. Chin J Biotechnol, 2006, 22(2):173-179. (in Chinese) , , , . b 2b 8 Vr . 3 , 2006, 22(2):173-179. 16 Yeh P, Landais D, Lemaitre M, et al. Design of yeast-secreted albumin deri
13、vatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci U S A, 1992, 89(5):1904-1908. 17 Ferre R, Badosa E, Feliu L, et al. Inhibition of plant-pathogenic bacteria by short synthetic cecropin A-melittin hybrid peptides. Appl Environ
14、 Microbiol, 2006, 72(5):3302-3308. 18 Anishetty S, Anishetty R, Pennathur G. Understanding mutations and protein stability through tripeptides. FEBS Lett, 2006, 580(8): 2071-2080. 19 Bogdanowich-Knipp SJ, Jois DS, Siahaan TJ. The effect of conformation on the solution stability of linear vs. cyclic
15、RGD peptides. J Pept Res, 1999, 53(5):523-529. 20 Cheng S, Craig WS, Mullen D, et al. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. J Med Chem, 1994, 37(1):1-8. 21 Mamadou AS, Annie M, Frederic L, et al. Synthesis o
16、f RGD amphiphilic cyclic peptide as fibrinogen or fibronectin antagonist. Lett Pept Sci, 1997, 4:455-461. 22 Siemion IZ, Gawlowska M, Krajewski K, et al. Analogs of RGDVY and GRGD peptides inhibit Mycobacterium kansasii phagocytosis. Peptides, 2003, 24(8):1109-1115. 23 Gilon C, Halle D, Chorev M, et
17、 al. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers, 1991, 31(6):745-750. 24 Bourne GT, Golding SW, McGeary RP, et al. The development and application of a novel safety-catch linker for BOC-based assembly of libraries of cyclic peptides. J Org Ch
18、em, 2001, 66(23):7706-7713. 25 Huang XY, Wang T, Xia CQ, et al. Synthesis of novel disulfide bond-bearing cyclopeptides. Chin J Org Chem, 2004, 24(12):1629- 1632. (in Chinse) lj , ! , 1. V , . c= ;ot . , 2004, 24(12):1629-1632. 26 Ranganathan D, Haridas V, Karle IL. Cystinophanes, a novel family of
19、aromatic-bridged cystine cyclic peptides:synthesis, crystal structure, molecular recognition, and conformational studies. J Am Chem Soc, 1998, 120(12):2695-2702. 27 Shreder K, Zhang L, Dang T, et al. Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue(MABE): a new ro
20、ute to cyclic peptides and peptidomimetics. J Med Chem, 1998, 41(14):2631-2635. 28 Han QW, Zhun XQ, Hu XB, et al. Synthesis of a family of ferrocene-bearing cyclo-pseudo-peptides by liquid method and molecular recognition. Chemical Res Chin Univ, 2002, 23(11):2076- 2079. (in Chinse) b - , k d , o ,
21、. = M ts0 MY . , 2002, 23(11):2076-2079. 29 Jensen KJ, Alsina J, Songster MF, et al. Backbone amide linker (BAL) strategy for solid-phase synthesis of c-terminal-modified and cyclic peptides. J Am Chem Soc, 1998, 120(22):5441-5452. 30 Siemion IZ, Gawlowska M, Krajewski K, et al. Analogs of RGDVY and
22、 GRGD peptides inhibit mycobacterium kansasii phagocytosis. Peptides, 2003, 24(8):1109-1115. 31 Berezowska I, Chung NN, Lemieux C, et al. Cyclic dermorphin tetrapeptide analogues obtained via ring-closing metathesis. Acta Biochim Pol, 2006, 53(1):73-76. 32 Tamilarasu N, Huq I, Rana TM. Design, synthesis, and biological activity of a cyclic peptide:an inhibitor of HIV-1 TAR interactions in human cells. Bioorg Med Lett, 2000, 10(9):971-974.
